infertility
Women's health · 2016–2022
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| progesterone Luteal phase support as part of an Assisted Reproductive Technology (ART) treatment cycle for infertile women. | Jul 2022 | Recommended with restriction | none received |
| follitropin alfa Infertility treatment in assisted reproductive technology (ART) and other follitropin alfa indications (anovulatory infertility, hypogonadotrophic… | Mar 2018 | Recommended with restriction | none received |
| follitropin alfa Controlled ovarian hyperstimulation in women undergoing assisted reproductive technology; treatment of anovulatory infertility in women unresponsive to… | Mar 2016 | Recommended with restriction | input received Access Australia |
Who spoke
Access Australia
What the PBS pays
$123M in government benefit over 2024–25, across 245,834 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| follitropin alfa | $113M |
| progesterone | $9.6M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.